Table 1 Baseline disease activity by treatment group.
| All randomised patients | Patients with evaluable radiographs | |||
|---|---|---|---|---|
| Group I (PBO/IFX), n = 52 | Group II (IFX/IFX), n = 52 | Group I (PBO/IFX), n = 35 | Group II (IFX/IFX), n = 37 | |
| Tender joint count (0–68), mean (SD) | 20.4 (12.1) | 23.7 (13.7) | 17.9 (10.1) | 22.6 (13.6) |
| Swollen joint count (0–66), mean (SD) | 14.7 (8.2) | 14.6 (7.5) | 14.2 (8.7) | 14.6 (7.8) |
| HAQ Disability Index (0–3), mean (SD) | 1.2 (0.7) | 1.2 (0.7) | 1.2 (0.7) | 1.0 (0.5) |
| CRP (mg/dl), mean (SD) | 31.1 (38.1) | 21.7 (27.0) | 34.3 (42.8) | 20.1 (26.4) |
| Patients with baseline use | ||||
| MTX | 65.4% | 46.2% | 70.6% | 37.8%* |
| Prednisone | 26.9% | 15.4% | 23.5% | 16.2% |
| Estimate baseline annual rate of | NA | NA | 3.8 (4.6) | 7.7 (18.7) |
| radiographic progression (modified | ||||
| vdH‐S points per year) | ||||
| Modified vdH‐S score | ||||
| Total | NA | NA | 32.3 (39.7) | 69.2 (94.9) |
| Hands | NA | NA | 20.3 (26.0) | 40.5 (56.4) |
| Feet | NA | NA | 11.3 (16.4) | 28.8 (44.6) |
CRP, C‐reactive protein; HAQ, Health Assessment Questionnaire; NA, not applicable.
*p<0.01 for IFX/IFX v PBO/IFX.